,,iv  #aai? ,,congress  #b;d ,session   
,h4 ,,res4 #aeji  ,,9 ,,! ,,h\se ,,(    
,,repres5tatives  ,septemb] #c1         
#bjbf,ms4 ,*u 7= h]self & ,mr4 ,kelly ( 
,p5nsylvania7 submitt$ ! foll[+         
resolution2 :i* 0 ref]r$ to ! ,committee
 on ,ov]sight & ,gov]nm5t ,re=m         
,,resolution  ,recogniz+ ! extraord9>y  
resili5ce & c\rage ( *ildr5 & families  
fight+ neurobla/oma & supports !        
incr$ible ef=t ( cl9icians & rese>*]s   
work+ to address ?is disease & express+ 
support = ,septemb] #c1 #bjbf1 to be    
designat$ z ,neurobla/oma ,aw>5ess ,day4
  ,:]eas neurobla/oma is ! mo/ common   
canc] 9 infants & ! mo/ common          
extracranial solid tumor 9 *ildhood2    
,:]eas !re are approximately #fjj to    
#hjj new cases ( neurobla/oma diagnos$  
ea* ye> 9 ! ,unit$ ,/ates2 ,:]eas       
neurobla/oma acc\nts = ab\t #h to #aj   
p]c5t ( all *ildhood canc]s &           
approximately #ae p]c5t ( *ildhood canc]
 dea?s2 ,:]eas approximately #ij p]c5t (
 neurobla/oma cases are diagnos$ be=e #e

 ye>s ( age1 ) _m cases occurr+ dur+    
infancy2 ,:]eas symptoms are (t5        
nonspecific1 :i* c delay diagnosis &    
treatm5t2 ,:]eas neurobla/oma acc\nts = 
a disproportionate %>e ( p$iatric canc] 
dea?s relative to its incid5ce2 ,:]eas  
high-risk neurobla/oma rema9s "o ( ! mo/
 difficult p$iatric canc]s to treat     
successfully2 ,:]eas ! e/imat$ #e-ye>   
survival rate = *ildr5 ) high-risk      
neurobla/oma is approximately #fc p]c5t2
 ,:]eas treatm5t = high-risk            
neurobla/oma typically requires int5sive
 multimodal !rapy1 includ+ *emo!rapy1   
surg]y1 radiation !rapy1 /em cell       
transplant1 & immuno!rapy2 ,:]eas       
survivors may exp]i5ce significant      
lifelong heal? complications1 includ+   
he>+ loss1 organ failure1 & subsequ5t   
malignancies2 ,:]eas *ildr5 )           
neurobla/oma (t5 require prolong$       
treatm5t & repeat$ hospitalizations2    
,:]eas anti-,,gd#b immuno!rapy has      
improv$ outcomes = *ildr5 ) high-risk   
neurobla/oma2  ,:]eas em]g+ !rapies1    

includ+ ,,c>-,t cell treatm5ts t>get+   
tumor antig5s su* z ,b#g-;,h#c1 are "u  
active inve/igation = relaps$ disease2  
,:]eas *ildhood canc]s1 includ+         
neurobla/oma1 hi/orically receive       
significantly less rese>* fund+ comp>$  
to adul?ood canc]s2 ,:]eas *ildr5 )     
high-risk or relaps$ neurobla/oma       
cont9ue to face limit$ effective        
treatm5t options & a high risk (        
relapse1 highlight+ ! ne$ = cont9u$     
rese>* & !rapeutic developm5t2 ,:]eas   
increas$ aw>5ess c support e>li]        
diagnosis1 improve outcomes1 & help     
drive inve/m5t 9 rese>* & treatm5t      
advancem5ts = p$iatric canc]s2 ,:]eas   
,septemb] is recogniz$ z ,*ildhood      
,canc] ,aw>5ess ,mon? 9 ! ,unit$ ,/ates2
 & ,:]eas ! ,h\se ( ,repres5tatives     
supports designat+ ,septemb] #c1 #bjbf1 
z ,neurobla/oma ,aw>5ess ,day3 ,n[1     
!re=e1 be x ,t ! ,h\se ( ,repres5tatives
 supports ! designation ( a             
,neurobla/oma ,aw>5ess ,day to provide a
 d$icat$ opportunity to recognize !     

extraord9>y resili5ce & c\rage ( *ildr5 
& families fight+ ?is disease & support 
! incr$ible ef=t ( cl9icians & rese>*]s 
work+ to address ?is disease4